Tamara Fountain, MD
Ophthalmic Plastic and Reconstructive Surgery · Deerfield, ILNPI 1033110978
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $821,217 of the $1,046,193 with a category attached, or 78.5%. Rxsight Inc accounts for 95.0% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $565,981 and has fallen 50.9% since, to $278,177 in 2025.
Across 64 payments — averaging $16,347 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$994K
- Sight Sciences, Inc.$48K
- Amgen$2K
- Oyster Point Pharma, Inc.$2K
- Alcon$143
- AstraZeneca$125
- plus $302 from 6 others
What the payments were for
- Consulting fees$218,43021%
- Speaking & faculty fees$821,21778%
- Travel & lodging$1,9790%
- Food & beverage$1,6670%
- Education$2,9000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 38 | $993,629 |
| Sight Sciences, Inc. | 11 | $47,819 |
| Amgen | 5 | $2,245 |
| Oyster Point Pharma, Inc. | 1 | $1,930 |
| Alcon | 2 | $143 |
| AstraZeneca | 1 | $125 |
| Mallinckrodt Enterprises LLC | 1 | $114 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $86 |
| Bausch & Lomb Americas Inc. | 1 | $45 |
| Biotissue Holdings Inc. | 1 | $24 |
| NEW World Medical,inc. | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$993,441
- RXSIGHT INJECTOR CARTRIDGE$993,441
- RXSIGHT INJECTOR HANDPIECE$993,441
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$993,441
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$565,919
- LIGHT ADJUSTABLE LENS (LAL)$427,522
- OMNI(R) SURGICAL SYSTEM (US)$47,819
- SION SURGICAL INSTRUMENT$47,819
- TEPEZZA$119
- AcrySof$116
- ACTHAR$114
How this compares
Too few ophthalmic plastic and reconstructive surgery providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 83 | $751 |
| Diazepam | 17 | $23 |
Paid to pharmacies, not to this prescriber.
Other ophthalmic plastic and reconstructive surgery in Deerfield
- Paul PhelpsChicago$141K
- Kenya WilliamsChicago$23K
- Liza CohenChicago$5K
- Krishna PatelWheaton$4K
- Stephen WinklerDes Plaines$3K
- Hassan ShahChicago$1K
- Jamie KeenHines$1K
- Duaa SharfiMerrionette Park$1K
- Olivia ChengChicago$1K
- Stacy Scofield-KaplanNaperville$803
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.